R&D channel feed

Nkar­ta breaks si­lence on CAR-NK ther­a­py for AML af­ter a year, shares tum­ble

Last year
Cell/Gene Tx

Aldeyra says its can­di­date won in chron­ic cough PhII, set­ting stage for bout with Mer­ck, GSK

Last year

Xen­tria and Meitheal ink li­cens­ing deal for rare lung dis­ease treat­ment in North Amer­i­ca

Last year
Deals

FDA ap­proves first of two UCB myas­the­nia gravis drugs, fol­low­ing Alex­ion and ar­genx’s lead

Last year
FDA+

Top drug from Sanofi’s $1.5B Kymab buy­out aces PhI­Ib in eczema

Last year

Lil­ly’s pipeline drug re­ta­tru­tide sets new thresh­old for weight loss at med­ical meet­ing re­veal

Last year

Ser­no­va says five di­a­betes pa­tients have now been tak­en off in­sulin af­ter 'cell pouch' ther­a­py

Last year

J&J touts PhII da­ta in rare blood dis­or­der as it plots a piv­otal study

Last year
Pharma

Look­ing to ex­pand Pyrukynd la­bel, Agios treks to­ward PhI­II in sick­le cell dis­ease

Last year

Ava­lo fails asth­ma PhII with lead can­di­date, shares crater

Last year

Fi­bro­Gen re­ports third PhI­II fail­ure in two months, this time in id­io­path­ic pul­monary fi­bro­sis

Last year

Pfiz­er picks GLP-1 tablet win­ner: Danuglipron for PhI­II

Last year
Pharma

Ex­clu­sive: The se­cret to de­sign­ing pro­tein drugs with AI? Gen­er­ate be­lieves it's cryo-EM at un­prece­dent­ed scale

Last year
AI
Discovery

No­vo Nordisk's oral semaglu­tide on par with in­jectable ver­sion in weight loss and safe­ty

Last year

Moon­Lake's PhII da­ta on skin dis­ease set it up against Cosen­tyx, UCB and oth­ers in IL-17 field

Last year

Ver­tex's cell ther­a­py gives ear­ly hope for wean­ing some type 1 di­a­betes pa­tients from in­sulin

Last year

CAR-T cell ther­a­py for myas­the­nia gravis shows promise in small study by Carte­sian Ther­a­peu­tics

Last year
Cell/Gene Tx

Roche stops de­vel­op­ment on an An­gel­man ther­a­py due to dis­ap­point­ing ef­fi­ca­cy, says it’s seek­ing ex­ter­nal part­ner

Last year
Pharma

Aslan out­li­cens­es atopic der­mati­tis an­ti­body in $138.5M deal

Last year
Deals

As Roivant read­ies for a UC clash with Mer­ck, CEO Matt Gline is can­did about keep­ing a com­pet­i­tive edge

Last year

Trail­ing Akero and 89bio, Boston Phar­ma­ceu­ti­cals posts ear­ly da­ta on its NASH in­jec­tion

Last year

UniQure un­veils mixed Hunt­ing­ton's gene ther­a­py da­ta, shares tank

Last year

GSK, Pfiz­er present key dura­bil­i­ty da­ta for RSV shots, as CDC pan­el scru­ti­nizes ri­val vac­cines

Last year

As­traZeneca stops PhI­Ia tri­al of in­haled asth­ma drug with Pieris, cra­ter­ing the Boston biotech's shares

Last year
First page Previous page 78798081828384 Next page Last page
A service from the Financial Times